ReviewPharmacology & therapeutics2011
Shielding the messenger (RNA): microRNA-based anticancer therapies.
Review in Pharmacology & therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 60 citations in OpenAlex.
- Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs.Cancer cell international · 2023Review
- MiR-467a-5p aggravates myocardial infarction by modulating ZEB1 expression in mice.Journal of molecular histology · 2021Article
- Develop a circular RNA-related regulatory network associated with prognosis of gastric cancer.Cancer medicine · 2020Article
- Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer.Nucleic acids research · 2019Review
- MicroRNA‑330‑5p inhibits osteosarcoma cell growth and invasion by targeting the proto‑oncogene survivin.Molecular medicine reports · 2019Article
- Aberrant splicing in B-cell acute lymphoblastic leukemia.Nucleic acids research · 2018Article
- PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.Seminars in cancer biology · 2018Review
- MicroRNA Control of TGF-β Signaling.International journal of molecular sciences · 2018Review
- MicroRNA-19a acts as a prognostic marker and promotes prostate cancer progression via inhibiting VPS37A expression.Oncotarget · 2018Article
- MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.Molecular cancer · 2017Article
- Targeting microRNAs as key modulators of tumor immune response.Journal of experimental & clinical cancer research : CR · 2016Review
- MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.Journal of ovarian research · 2015Article
- Advances in miRNA-Mediated Mucin Regulation.Current pharmacology reports · 2015Article
- Function and clinical potential of microRNAs in hepatocellular carcinoma.Oncology letters · 2015Article
- MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells.Journal of translational medicine · 2015Article
- MicroRNA-1290 promotes esophageal squamous cell carcinoma cell proliferation and metastasis.World journal of gastroenterology · 2015Article
- RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.Molecular cancer · 2015Article
- MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.Drug design, development and therapy · 2015Article
- Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.PloS one · 2015Article
- MicroRNA 130b enhances drug resistance in human ovarian cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
It has been a decade since scientists realized that microRNAs (miRNAs) are not an oddity invented by worms to regulate gene expression at post-transcriptional levels. Rather, many of these 21-22-nucleotide-short RNAs exist in invertebrates and vertebrates alike and some of them are in fact highly conserved. miRNAs are now recognized as an important class of non-coding small RNAs that inhibit gene expression by targeting mRNA stability and translation. In the last ten years, our knowledge of the miRNAs world was expanding at vertiginous speed, propelled by the development of computational engines for miRNA identification and target prediction, biochemical tools and techniques to modulate miRNA activity, and last but not least, the emergence of miRNA-centric animal models. One important conclusion that has emerged from this effort is that many microRNAs and their cognate targets are strongly implicated in cancer, either as oncogenes or tumor and metastasis suppressors. In this review we will discuss the diverse role that miRNAs play in cancer initiation and progression and also the tools with which miRNA expression could be corrected in vivo. While the idea of targeting microRNAs towards therapeutic ends is getting considerable traction, basic, translational, and clinical research done in the next few years will tell whether this promise is well-founded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.